Welcome to our dedicated page for Polyrizon SEC filings (Ticker: PLRZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Polyrizon’s SEC reports routinely span hundreds of pages packed with clinical trial data, patent milestones, and cash-runway forecasts—critical details that can overwhelm even seasoned biotech investors. Missing a single footnote on R&D obligations or a late-night 8-K material event could mean overlooking a pivotal inflection point.
Stock Titan solves that pain. Our AI digests every 10-K annual report, 10-Q quarterly earnings report, and registration statement, translating technical language about intranasal hydrogel science into clear insights. Want to spot dilution risks before they happen? Our algorithms flag shelf offerings the moment they appear. Need "Polyrizon insider trading Form 4 transactions"? We stream Form 4 filings in real time, highlighting executive stock moves so you always know who is buying or selling. Search traffic naturally lands here for phrases such as "understanding Polyrizon SEC documents with AI" or "Polyrizon earnings report filing analysis"—because we answer those questions directly.
Beyond raw documents, you’ll find:
- Side-by-side AI summaries that explain clinical-stage burn rates in the Polyrizon annual report 10-K simplified
- Immediate alerts on Polyrizon Form 4 insider transactions real-time, including option grants tied to milestone achievements
- Concise breakdowns of patent-portfolio disclosures in each Polyrizon 8-K material events explained filing
- Clear tables connecting proxy data to "Polyrizon proxy statement executive compensation" so you can benchmark leadership incentives
Every document, from S-1 shelf registrations to complex merger exhibits, is indexed and updated as soon as EDGAR releases them. With Stock Titan’s expert analysis, biotech intricacy becomes readable context—empowering you to make confident, timely decisions.
Polyrizon Ltd. (PLRZ) is implementing a reverse share split of its ordinary shares at a 1-for-6 ratio, so every six existing ordinary shares will be consolidated into one new ordinary share. The company states that trading on the Nasdaq Capital Market on a split-adjusted basis will begin on November 28, 2025.
After the reverse split, the number of issued and outstanding ordinary shares will be adjusted from 6,250,053 to 1,041,676, while the authorized share capital will remain unchanged. Fractional shares will not be issued; fractions greater than 0.5 will be rounded up to the nearest whole share. The company will also make proportionate adjustments to the per share exercise price and the number of ordinary shares underlying all outstanding warrants and options.
Polyrizon Ltd. filed a Form F-3 shelf registration to offer and sell, from time to time after effectiveness, up to $50,000,000 of securities, including ordinary shares, warrants, and units. Each takedown will be detailed in a future prospectus supplement that sets pricing and specific terms.
The company may sell securities directly, through agents, dealers or underwriters, and may use methods such as at-the-market offerings, negotiated transactions, or block trades as described in its plan of distribution. Net proceeds will be used for general corporate purposes, including operations, capital expenditures, business and technology development, and potential strategic opportunities. Polyrizon’s ordinary shares trade on the Nasdaq Capital Market under PLRZ. Certain warrants may include 4.99% or 9.99% beneficial ownership limitations on exercise.
Polyrizon Ltd. furnished a Form 6-K that attaches a press release titled “Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation.”
The filing states that the first four paragraphs of this press release are incorporated by reference into the company’s Registration Statements on Form S-8, to be part of those registrations from the date this report is submitted, to the extent not superseded by later filings.
FAQ
What is the current stock price of Polyrizon (PLRZ)?
What is the market cap of Polyrizon (PLRZ)?
